Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease (AD)

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease (AD)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib/ciprofloxacin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept
  • Acronyms RoAD
  • Sponsors NeuroSense Therapeutics

    • Most Recent Events

    • 22 Apr 2024 According to a NeuroSense Therapeutics media release, the company to collaborate with Genetika+ technology that derives frontal cortex neurons from individual patients' blood to quantify drug-induced neuronal plasticity in vitro to optimize this trial.
    • 14 Dec 2023 Status changed from planning to recruiting.
    • 28 Nov 2023 According to a NeuroSense Therapeutics media release, company expects to enroll first patient in this Phase 2 Alzheimer's disease study in Dec 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top